Cancer Supportive Care Market Size 2025-2029
The cancer supportive care market size is forecast to increase by USD 6.7 billion, at a CAGR of 4.4% between 2024 and 2029.
The global cancer supportive care market is expanding due to the rising incidence of cancer cases worldwide, which necessitates treatments that enhance patient quality of life. This driver increases the demand for effective symptom management solutions and supportive care protocols. The advent of biosimilars is a key trend, making therapies more accessible and fostering innovation within the broader cancer immunotherapy market and cancer diagnostics market. These alternatives to original biologics help reduce treatment costs, thereby expanding patient access to essential supportive care, including pain management drugs and treatments for chemotherapy-induced neutropenia.While the introduction of biosimilars helps address affordability, the high cost of cancer treatment remains a primary challenge, impacting the breast cancer therapeutics market and related sectors. This financial burden affects patient compliance with therapies for side-effect mitigation and can compromise the overall effectiveness of care. The economic pressure often forces patients to prioritize primary treatments over supportive therapies, potentially affecting outcomes in the cancer supportive care market. The focus remains on balancing innovation, such as developing novel antiemetic therapies, with the need for accessible and affordable patient-centric solutions across the care continuum.
What will be the Size of the Cancer Supportive Care Market during the forecast period?
Explore in-depth regional segment analysis with market size data - historical 2019 - 2023 and forecasts 2025-2029 - in the full report.
Request Free Sample
The global cancer supportive care market is shaped by the continuous need for chemotherapy-induced anemia and chemotherapy-induced neutropenia management. Innovations in antiemetic therapies and pain management drugs are crucial. The adoption of supportive care protocols is rising to improve treatment adherence and manage skeletal-related events. This dynamic environment, influenced by the cancer immunotherapy market, demands effective myelosuppression mitigation strategies to enhance patient quality of life.Strategic imperatives include developing patient-centric solutions and personalized therapies to address the complexities of cancer pain management and cinv treatment. The focus on biosimilar manufacturing and navigating reimbursement policies is intensifying. The integration of digital monitoring tools and home-based care models reflects a shift toward more accessible care. Palliative care services and nutritional support interventions are becoming standard components of holistic patient care within the cancer supportive care market and broader cancer biologics field.Challenges such as managing side effects from targeted cancer therapies and androgen deprivation therapy are driving innovation in symptom management solutions. The development of treatments for oral mucositis and cancer cachexia continues to be a priority. As febrile neutropenia prevention becomes more critical, the market is responding with advanced granulocyte colony-stimulating factors and erythropoiesis stimulating agents. These activities highlight the evolving nature of the breast cancer liquid biopsy market and its supporting ecosystem.
How is this Cancer Supportive Care Industry segmented?
The cancer supportive care industry research report provides comprehensive data (region-wise segment analysis), with forecasts and estimates in "USD million" for the period 2025-2029, as well as historical data from 2019 - 2023 for the following segments.
- Therapeutic area
- Chemotherapy-induced anemia
- Chemotherapy-induced neutropenia
- Cancer pain
- CINV
- Others
- Distribution channel
- Hospitals pharmacies
- Drug stores and retail pharmacies
- Online providers
- Application
- Breast cancer
- Colorectal cancer
- Stomach cancer
- Liver cancer
- Prostate cancer
- Geography
- North America
- Europe
- UK
- Germany
- France
- Italy
- The Netherlands
- Spain
- Asia
- Rest of World (ROW)
By Therapeutic Area Insights
The chemotherapy-induced anemia segment is estimated to witness significant growth during the forecast period.
Therapies for chemotherapy-induced anemia (CIA) are a critical and evolving segment of cancer supportive care. Anemia is a common complication for patients undergoing chemotherapy, causing significant fatigue and reducing quality of life, which can lead to interruptions in primary cancer treatment. The therapeutic landscape has traditionally relied on erythropoiesis-stimulating agents and iron supplementation. However, the segment is now seeing significant innovation aimed at developing novel therapeutic approaches with improved safety and efficacy profiles for better patient-centric solutions.
A key development is the emergence of new oral medications, such as hypoxia-inducible factor prolyl hydroxylase (HIF-PH) inhibitors, which offer greater patient convenience and adherence compared to injectables. With some developing markets representing over 13% of the global opportunity, there is a strong focus on creating more accessible treatment options. Research continues to explore alternative pathways to stimulate red blood cell production, addressing the multifactorial nature of CIA and ensuring a growing demand for effective treatments.
Request Free Sample
The Chemotherapy-induced anemia segment was valued at USD 6.5 billion in 2019 and showed a gradual increase during the forecast period.
Regional Analysis
North America is estimated to contribute 37.6% to the growth of the global market during the forecast period.Technavio’s analysts have elaborately explained the regional trends and drivers that shape the market during the forecast period.
Request Free Sample
The North America cancer supportive care market is the largest geographical segment and is expected to maintain its position. This dominance is driven by factors such as a high prevalence of cancer, an advanced healthcare infrastructure, and significant healthcare spending. A key trend in North America is the growing adoption of biosimilars and generics, which helps expand patient access to crucial supportive care medications. The region demonstrates a strong emphasis on managing the side effects of therapies to improve patient quality of life.
North America contributes significantly to market expansion, accounting for over 37% of the anticipated incremental development. The region's dynamic landscape is marked by continuous innovation, supportive care protocols, and a focus on improving patient outcomes. Robust research and development activities, along with a generally favorable environment for reimbursement of pain management drugs and other therapies, continue to drive market activity. This combination of factors ensures that North America remains a pivotal region in the global cancer supportive care sector.
Market Dynamics
Our researchers analyzed the data with 2024 as the base year, along with the key drivers, trends, and challenges. A holistic analysis of drivers will help companies refine their marketing strategies to gain a competitive advantage.
The global cancer supportive care market is rapidly evolving, driven by the need for enhanced patient outcomes and quality of life. Key market focuses include developing cost-effective supportive care solutions and refining side effect management protocols. Innovations in managing chemotherapy-induced neutropenia risk and preventing chemotherapy-induced nausea vomiting are paramount. Furthermore, specialized approaches such as targeted therapy supportive care and specific interventions like supportive care for breast cancer and supportive care in colorectal cancer are gaining traction. The introduction of biosimilars in cancer supportive care offers new avenues for affordability, while robust strategies for supportive care for bone metastases remain critical. Ultimately, all these efforts converge on the primary goal of improving patient treatment adherence throughout the care continuum.Addressing the multifaceted nature of cancer care involves integrating diverse services and technologies. The expanding role of palliative care services and the implementation of effective strategies for cancer pain relief are central to this effort. As the industry shifts towards patient-centric approaches, home-based cancer care models are being adopted, supported by digital tools for symptom monitoring. Attention is also being given to the psychological impact of cancer treatment and the importance of nutritional support in oncology patients. However, providers continue to navigate supportive care reimbursement challenges. For long-term patient well-being, comprehensive survivorship care for cancer patients is essential, encompassing specific challenges like managing androgen deprivation side effects from prostate cancer treatment and managing immune-related adverse events from newer immunotherapies.
What are the key market drivers leading to the rise in the adoption of Cancer Supportive Care Industry?
- The rising global incidence of cancer is a significant driver for the supportive care market, creating a higher demand for treatments that improve patient outcomes and quality of life.
The increasing number of cancer diagnoses worldwide, driven by lifestyle shifts, aging populations, and environmental risk factors, creates a sustained demand for treatments that improve patient quality of life. Supportive care protocols are crucial for enhancing treatment adherence and managing complications from aggressive therapies. As diagnostic advancements enable earlier detection, more patients require side-effect mitigation strategies. Healthcare systems are integrating comprehensive symptom management solutions to support better patient outcomes, with over 37% of incremental market growth originating from key developed economies, highlighting the focus on holistic patient care.The severe side effects associated with cancer treatments like chemotherapy and radiation, including nausea, pain, and fatigue, directly impact a patient's well-being and can limit the effectiveness of the primary therapy. This increases demand for supportive care products and services designed for myelosuppression mitigation. The emphasis on personalized medicine and patient-centric solutions underscores the need for effective management of treatment-related complications. Healthcare facilities are increasingly investing in supportive care protocols to shorten hospital stays, improve compliance, and reduce overall healthcare costs, which in turn accelerates the adoption of these vital interventions.
What are the market trends shaping the Cancer Supportive Care Industry?
- The emergence of biosimilars in cancer-related treatments is significantly altering the therapeutic landscape by making life-saving therapies more accessible.
The introduction of biosimilars is altering the therapeutic landscape by providing alternatives to original biologic drugs with comparable safety and efficacy, enhancing the cancer immunotherapy market. This trend makes essential treatments for febrile neutropenia prevention and other complications more accessible. As biologics face patent expiration, companies are increasing investment in biosimilar research, which fosters market competition and drives innovation in drug formulation. With over 26% of market opportunity concentrated in established healthcare systems, the growing acceptance of biosimilars plays a crucial role in shaping the future of the cancer supportive care market and improving overall healthcare affordability through cost-effective supportive care protocols.Outsourcing biosimilar manufacturing activities to specialized contract manufacturing organizations has become a key strategy for many pharmaceutical firms. This approach allows companies to utilize specialized expertise, lower operational costs, and quicken production schedules for various supportive care protocols. By outsourcing, organizations can concentrate on core areas such as research and marketing while ensuring high-quality, scalable manufacturing of vital treatments. This model mitigates risks tied to large-scale production, like regulatory compliance challenges, and facilitates a more agile response to global demand for therapies, including emerging cancer biologics, without requiring substantial capital investment.
What challenges does the Cancer Supportive Care Industry face during its growth?
- The significant financial burden associated with cancer treatment remains one of the most substantial challenges affecting the supportive care market.
The high financial burden of cancer treatment presents a significant challenge for the supportive care market. Advanced therapies and prolonged treatment regimens contribute to substantial costs, often making it difficult for patients to access adequate care and affecting compliance with supportive care protocols. This economic strain limits the affordability of essential symptom management solutions, such as anti-nausea medications, pain management drugs, and growth factors. Consequently, patients may be forced to prioritize primary treatments over supportive care, which can compromise their quality of life during therapy.In developed economies, which constitute over 22% of the market opportunity, the rising adoption of targeted cancer therapies is reshaping treatment paradigms. While precise, these therapies may lessen the perceived need for traditional supportive care interventions for side-effect mitigation. This creates challenges for manufacturers in sustaining demand for established supportive care products. Furthermore, these advanced treatments often demand specialized monitoring, potentially limiting the utility of generalized supportive care. This environment necessitates innovation toward more integrated, therapy-specific care solutions to complement evolving treatment patterns.
Exclusive Customer Landscape
The cancer supportive care market forecasting report includes the adoption lifecycle of the market, covering from the innovator’s stage to the laggard’s stage. It focuses on adoption rates in different regions based on penetration. Furthermore, the cancer supportive care market report also includes key purchase criteria and drivers of price sensitivity to help companies evaluate and develop their market growth analysis strategies.
Customer Landscape
Key Companies & Market Insights
Companies are implementing various strategies, such as strategic alliances, cancer supportive care market forecast, partnerships, mergers and acquisitions, geographical expansion, and product/service launches, to enhance their presence in the industry.
Amgen Inc. - The company provides a portfolio of cancer supportive care therapies focused on managing critical treatment-related complications. Key offerings include treatments designed to address hematological side effects, such as a reduction in white blood cell counts induced by chemotherapy. Additionally, the portfolio includes agents for the prevention of skeletal-related events in patients whose cancer has spread to the bone, aiming to preserve bone health and improve patient quality of life during the course of their disease.
The industry research and growth report includes detailed analyses of the competitive landscape of the market and information about key companies, including:
- Amgen Inc.
- APR Applied Pharma Research SA
- Baxter International Inc.
- Bayer AG
- Daiichi Sankyo Co. Ltd.
- F. Hoffmann La Roche Ltd.
- GlaxoSmithKline Plc
- Helsinn Healthcare SA
- Heron Therapeutics Inc.
- Johnson and Johnson Services Inc.
- Kyowa Kirin Co. Ltd.
- Merck and Co. Inc.
- Novartis AG
- Pfizer Inc.
- Sanofi SA
- Sun Pharmaceutical Industries Ltd.
- Teva Pharmaceutical Industries Ltd.
Qualitative and quantitative analysis of companies has been conducted to help clients understand the wider business environment as well as the strengths and weaknesses of key industry players. Data is qualitatively analyzed to categorize companies as pure play, category-focused, industry-focused, and diversified; it is quantitatively analyzed to categorize companies as dominant, leading, strong, tentative, and weak.
Recent Development and News in Cancer Supportive Care Market
In June 2024, Bayer presented new data on Nubeqa for prostate cancer at the American Society of Clinical Oncology (ASCO) annual meeting, highlighting its role in treatment and the associated need for managing side effects like fatigue, which requires supportive care.In May 2024, Amgen featured new data across its oncology portfolio at the ASCO meeting, including updates on treatments where managing side effects through supportive care is crucial for patient adherence and quality of life.In March 2024, Novartis announced positive results from a Phase III trial of Pluvicto for a specific type of metastatic prostate cancer, reinforcing the need for effective supportive care to manage treatment-related side effects such as myelosuppression.
Research Analyst Overview
The global cancer supportive care market is defined by its continuous adaptation to manage complex treatment side effects. A primary focus is on myelosuppression mitigation, addressing conditions like chemotherapy-induced neutropenia and chemotherapy-induced anemia through the use of granulocyte colony-stimulating factors and erythropoiesis stimulating agents. Concurrently, advances in cinv treatment, cancer pain management, and emerging cancer cachexia therapies are critical. The management of complications such as skeletal-related events from bone metastases management further shapes the therapeutic landscape. These symptom management solutions, including advanced antiemetic therapies, are integral to improving patient quality of life and are guided by supportive care protocols designed for comprehensive side-effect mitigation and febrile neutropenia prevention against targeted cancer therapies.The market's evolution is increasingly oriented toward holistic patient care and patient-centric solutions, with the sector projected to expand by nearly 42% over the next decade. This paradigm integrates palliative care services, nutritional support interventions, and psychological counseling services into care continuums. The adoption of digital monitoring tools facilitates new home-based care models and remote patient monitoring, enhancing both treatment adherence improvement and patient quality of life. Furthermore, the economic landscape is being reshaped by reimbursement policies favoring value-based care and a strong pharmacoeconomic value proposition. The availability of options from biosimilar manufacturing and the implementation of robust clinical practice guidelines and patient navigation services underscore a move toward accessible, personalized therapies for complication management and oral mucositis treatment.
Dive into Technavio’s robust research methodology, blending expert interviews, extensive data synthesis, and validated models for unparalleled Cancer Supportive Care Market insights. See full methodology.
|
Market Scope
|
|
Report Coverage
|
Details
|
|
Page number
|
314
|
|
Base year
|
2024
|
|
Historic period
|
2019 - 2023 |
|
Forecast period
|
2025-2029
|
|
Growth momentum & CAGR
|
Accelerating at a CAGR of 4.4%
|
|
Market growth 2024-2029
|
USD 6.7 billion
|
|
Market structure
|
Fragmented
|
|
YoY growth 2024-2029(%)
|
4.1%
|
|
Key countries
|
US, Canada, Mexico, UK, Germany, France, Italy, The Netherlands, Spain, China, Japan, India, South Korea, Indonesia, Brazil, Saudi Arabia, Argentina, Australia, UAE, Colombia, South Africa, Israel, Turkey
|
|
Competitive landscape
|
Leading Companies, Market Positioning of Companies, Competitive Strategies, and Industry Risks
|
Request Free Sample
What are the Key Data Covered in this Cancer Supportive Care Market Research and Growth Report?
- CAGR of the Cancer Supportive Care industry during the forecast period
- Detailed information on factors that will drive the growth and forecasting between 2024 and 2029
- Precise estimation of the size of the market and its contribution of the industry in focus to the parent market
- Accurate predictions about upcoming growth and trends and changes in consumer behaviour
- Growth of the market across North America, Europe, Asia, Rest of World (ROW)
- Thorough analysis of the market’s competitive landscape and detailed information about companies
- Comprehensive analysis of factors that will challenge the cancer supportive care market growth of industry companies
We can help! Our analysts can customize this cancer supportive care market research report to meet your requirements.
Get in touch
1 Executive Summary
- 1 Executive Summary
- 1.1 Market overview
- Executive Summary - Chart on Market Overview
- Executive Summary - Data Table on Market Overview
- Executive Summary - Chart on Global Market Characteristics
- Executive Summary - Chart on Market by Geography
- Executive Summary - Chart on Market Segmentation by Therapeutic Area
- Executive Summary - Chart on Market Segmentation by Distribution Channel
- Executive Summary - Chart on Market Segmentation by Application
- Executive Summary - Chart on Incremental Growth
- Executive Summary - Data Table on Incremental Growth
- Executive Summary - Chart on Company Market Positioning
2 Technavio Analysis
- 2 Technavio Analysis
- 2.1 Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria
- Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria
- 2.2 Criticality of inputs and Factors of differentiation
- Chart on Overview on criticality of inputs and factors of differentiation
- 2.3 Factors of disruption
- Chart on Overview on factors of disruption
- 2.4 Impact of drivers and challenges
- Chart on Impact of drivers and challenges in 2024 and 2029
3 Market Landscape
- 3 Market Landscape
- 3.1 Market ecosystem
- Chart on Parent Market
- Data Table on - Parent Market
- 3.2 Market characteristics
- Chart on Market characteristics analysis
- 3.3 Value chain analysis
- Chart on Value chain analysis
4 Market Sizing
- 4 Market Sizing
- 4.1 Market definition
- Data Table on Offerings of companies included in the market definition
- 4.2 Market segment analysis
- 4.3 Market size 2024
- 4.4 Market outlook: Forecast for 2024-2029
- Chart on Global - Market size and forecast 2024-2029 ($ billion)
- Data Table on Global - Market size and forecast 2024-2029 ($ billion)
- Chart on Global Market: Year-over-year growth 2024-2029 (%)
- Data Table on Global Market: Year-over-year growth 2024-2029 (%)
5 Historic Market Size
- 5 Historic Market Size
- 5.1 Global Cancer Supportive Care Market 2019 - 2023
- Historic Market Size - Data Table on Global Cancer Supportive Care Market 2019 - 2023 ($ billion)
- 5.2 Therapeutic Area segment analysis 2019 - 2023
- Historic Market Size - Therapeutic Area Segment 2019 - 2023 ($ billion)
- 5.3 Distribution Channel segment analysis 2019 - 2023
- Historic Market Size - Distribution Channel Segment 2019 - 2023 ($ billion)
- 5.4 Application segment analysis 2019 - 2023
- Historic Market Size - Application Segment 2019 - 2023 ($ billion)
- 5.5 Geography segment analysis 2019 - 2023
- Historic Market Size - Geography Segment 2019 - 2023 ($ billion)
- 5.6 Country segment analysis 2019 - 2023
- Historic Market Size - Country Segment 2019 - 2023 ($ billion)
6 Qualitative Analysis
- 6 Qualitative Analysis
- 6.1 The AI impact on Global Cancer Supportive Care Market
7 Five Forces Analysis
- 7 Five Forces Analysis
- 7.1 Five forces summary
- Five forces analysis - Comparison between 2024 and 2029
- 7.2 Bargaining power of buyers
- Bargaining power of buyers - Impact of key factors 2024 and 2029
- 7.3 Bargaining power of suppliers
- Bargaining power of suppliers - Impact of key factors in 2024 and 2029
- 7.4 Threat of new entrants
- Threat of new entrants - Impact of key factors in 2024 and 2029
- 7.5 Threat of substitutes
- Threat of substitutes - Impact of key factors in 2024 and 2029
- 7.6 Threat of rivalry
- Threat of rivalry - Impact of key factors in 2024 and 2029
- 7.7 Market condition
- Chart on Market condition - Five forces 2024 and 2029
8 Market Segmentation by Therapeutic Area
- 8 Market Segmentation by Therapeutic Area
- 8.1 Market segments
- Chart on Therapeutic Area - Market share 2024-2029 (%)
- Data Table on Therapeutic Area - Market share 2024-2029 (%)
- 8.2 Comparison by Therapeutic Area
- Chart on Comparison by Therapeutic Area
- Data Table on Comparison by Therapeutic Area
- 8.3 Chemotherapy-induced anemia - Market size and forecast 2024-2029
- Chart on Chemotherapy-induced anemia - Market size and forecast 2024-2029 ($ billion)
- Data Table on Chemotherapy-induced anemia - Market size and forecast 2024-2029 ($ billion)
- Chart on Chemotherapy-induced anemia - Year-over-year growth 2024-2029 (%)
- Data Table on Chemotherapy-induced anemia - Year-over-year growth 2024-2029 (%)
- 8.4 Chemotherapy-induced neutropenia - Market size and forecast 2024-2029
- Chart on Chemotherapy-induced neutropenia - Market size and forecast 2024-2029 ($ billion)
- Data Table on Chemotherapy-induced neutropenia - Market size and forecast 2024-2029 ($ billion)
- Chart on Chemotherapy-induced neutropenia - Year-over-year growth 2024-2029 (%)
- Data Table on Chemotherapy-induced neutropenia - Year-over-year growth 2024-2029 (%)
- 8.5 Cancer pain - Market size and forecast 2024-2029
- Chart on Cancer pain - Market size and forecast 2024-2029 ($ billion)
- Data Table on Cancer pain - Market size and forecast 2024-2029 ($ billion)
- Chart on Cancer pain - Year-over-year growth 2024-2029 (%)
- Data Table on Cancer pain - Year-over-year growth 2024-2029 (%)
- 8.6 CINV - Market size and forecast 2024-2029
- Chart on CINV - Market size and forecast 2024-2029 ($ billion)
- Data Table on CINV - Market size and forecast 2024-2029 ($ billion)
- Chart on CINV - Year-over-year growth 2024-2029 (%)
- Data Table on CINV - Year-over-year growth 2024-2029 (%)
- 8.7 Others - Market size and forecast 2024-2029
- Chart on Others - Market size and forecast 2024-2029 ($ billion)
- Data Table on Others - Market size and forecast 2024-2029 ($ billion)
- Chart on Others - Year-over-year growth 2024-2029 (%)
- Data Table on Others - Year-over-year growth 2024-2029 (%)
- 8.8 Market opportunity by Therapeutic Area
- Market opportunity by Therapeutic Area ($ billion)
- Data Table on Market opportunity by Therapeutic Area ($ billion)
9 Market Segmentation by Distribution Channel
- 9 Market Segmentation by Distribution Channel
- 9.1 Market segments
- Chart on Distribution Channel - Market share 2024-2029 (%)
- Data Table on Distribution Channel - Market share 2024-2029 (%)
- 9.2 Comparison by Distribution Channel
- Chart on Comparison by Distribution Channel
- Data Table on Comparison by Distribution Channel
- 9.3 Hospitals pharmacies - Market size and forecast 2024-2029
- Chart on Hospitals pharmacies - Market size and forecast 2024-2029 ($ billion)
- Data Table on Hospitals pharmacies - Market size and forecast 2024-2029 ($ billion)
- Chart on Hospitals pharmacies - Year-over-year growth 2024-2029 (%)
- Data Table on Hospitals pharmacies - Year-over-year growth 2024-2029 (%)
- 9.4 Drug stores and retail pharmacies - Market size and forecast 2024-2029
- Chart on Drug stores and retail pharmacies - Market size and forecast 2024-2029 ($ billion)
- Data Table on Drug stores and retail pharmacies - Market size and forecast 2024-2029 ($ billion)
- Chart on Drug stores and retail pharmacies - Year-over-year growth 2024-2029 (%)
- Data Table on Drug stores and retail pharmacies - Year-over-year growth 2024-2029 (%)
- 9.5 Online providers - Market size and forecast 2024-2029
- Chart on Online providers - Market size and forecast 2024-2029 ($ billion)
- Data Table on Online providers - Market size and forecast 2024-2029 ($ billion)
- Chart on Online providers - Year-over-year growth 2024-2029 (%)
- Data Table on Online providers - Year-over-year growth 2024-2029 (%)
- 9.6 Market opportunity by Distribution Channel
- Market opportunity by Distribution Channel ($ billion)
- Data Table on Market opportunity by Distribution Channel ($ billion)
10 Market Segmentation by Application
- 10 Market Segmentation by Application
- 10.1 Market segments
- Chart on Application - Market share 2024-2029 (%)
- Data Table on Application - Market share 2024-2029 (%)
- 10.2 Comparison by Application
- Chart on Comparison by Application
- Data Table on Comparison by Application
- 10.3 Breast cancer - Market size and forecast 2024-2029
- Chart on Breast cancer - Market size and forecast 2024-2029 ($ billion)
- Data Table on Breast cancer - Market size and forecast 2024-2029 ($ billion)
- Chart on Breast cancer - Year-over-year growth 2024-2029 (%)
- Data Table on Breast cancer - Year-over-year growth 2024-2029 (%)
- 10.4 Colorectal cancer - Market size and forecast 2024-2029
- Chart on Colorectal cancer - Market size and forecast 2024-2029 ($ billion)
- Data Table on Colorectal cancer - Market size and forecast 2024-2029 ($ billion)
- Chart on Colorectal cancer - Year-over-year growth 2024-2029 (%)
- Data Table on Colorectal cancer - Year-over-year growth 2024-2029 (%)
- 10.5 Stomach cancer - Market size and forecast 2024-2029
- Chart on Stomach cancer - Market size and forecast 2024-2029 ($ billion)
- Data Table on Stomach cancer - Market size and forecast 2024-2029 ($ billion)
- Chart on Stomach cancer - Year-over-year growth 2024-2029 (%)
- Data Table on Stomach cancer - Year-over-year growth 2024-2029 (%)
- 10.6 Liver cancer - Market size and forecast 2024-2029
- Chart on Liver cancer - Market size and forecast 2024-2029 ($ billion)
- Data Table on Liver cancer - Market size and forecast 2024-2029 ($ billion)
- Chart on Liver cancer - Year-over-year growth 2024-2029 (%)
- Data Table on Liver cancer - Year-over-year growth 2024-2029 (%)
- 10.7 Prostate cancer - Market size and forecast 2024-2029
- Chart on Prostate cancer - Market size and forecast 2024-2029 ($ billion)
- Data Table on Prostate cancer - Market size and forecast 2024-2029 ($ billion)
- Chart on Prostate cancer - Year-over-year growth 2024-2029 (%)
- Data Table on Prostate cancer - Year-over-year growth 2024-2029 (%)
- 10.8 Market opportunity by Application
- Market opportunity by Application ($ billion)
- Data Table on Market opportunity by Application ($ billion)
11 Customer Landscape
- 11 Customer Landscape
- 11.1 Customer landscape overview
- Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria
12 Geographic Landscape
- 12 Geographic Landscape
- 12.1 Geographic segmentation
- Chart on Market share by geography 2024-2029 (%)
- Data Table on Market share by geography 2024-2029 (%)
- 12.2 Geographic comparison
- Chart on Geographic comparison
- Data Table on Geographic comparison
- 12.3 North America - Market size and forecast 2024-2029
- Chart on North America - Market size and forecast 2024-2029 ($ billion)
- Data Table on North America - Market size and forecast 2024-2029 ($ billion)
- Chart on North America - Year-over-year growth 2024-2029 (%)
- Data Table on North America - Year-over-year growth 2024-2029 (%)
- Chart on Regional Comparison - North America
- Data Table on Regional Comparison - North America
- 12.3.1 US - Market size and forecast 2024-2029
- Chart on US - Market size and forecast 2024-2029 ($ billion)
- Data Table on US - Market size and forecast 2024-2029 ($ billion)
- Chart on US - Year-over-year growth 2024-2029 (%)
- Data Table on US - Year-over-year growth 2024-2029 (%)
- 12.3.2 Canada - Market size and forecast 2024-2029
- Chart on Canada - Market size and forecast 2024-2029 ($ billion)
- Data Table on Canada - Market size and forecast 2024-2029 ($ billion)
- Chart on Canada - Year-over-year growth 2024-2029 (%)
- Data Table on Canada - Year-over-year growth 2024-2029 (%)
- 12.3.3 Mexico - Market size and forecast 2024-2029
- Chart on Mexico - Market size and forecast 2024-2029 ($ billion)
- Data Table on Mexico - Market size and forecast 2024-2029 ($ billion)
- Chart on Mexico - Year-over-year growth 2024-2029 (%)
- Data Table on Mexico - Year-over-year growth 2024-2029 (%)
- 12.4 Europe - Market size and forecast 2024-2029
- Chart on Europe - Market size and forecast 2024-2029 ($ billion)
- Data Table on Europe - Market size and forecast 2024-2029 ($ billion)
- Chart on Europe - Year-over-year growth 2024-2029 (%)
- Data Table on Europe - Year-over-year growth 2024-2029 (%)
- Chart on Regional Comparison - Europe
- Data Table on Regional Comparison - Europe
- 12.4.1 UK - Market size and forecast 2024-2029
- Chart on UK - Market size and forecast 2024-2029 ($ billion)
- Data Table on UK - Market size and forecast 2024-2029 ($ billion)
- Chart on UK - Year-over-year growth 2024-2029 (%)
- Data Table on UK - Year-over-year growth 2024-2029 (%)
- 12.4.2 Germany - Market size and forecast 2024-2029
- Chart on Germany - Market size and forecast 2024-2029 ($ billion)
- Data Table on Germany - Market size and forecast 2024-2029 ($ billion)
- Chart on Germany - Year-over-year growth 2024-2029 (%)
- Data Table on Germany - Year-over-year growth 2024-2029 (%)
- 12.4.3 France - Market size and forecast 2024-2029
- Chart on France - Market size and forecast 2024-2029 ($ billion)
- Data Table on France - Market size and forecast 2024-2029 ($ billion)
- Chart on France - Year-over-year growth 2024-2029 (%)
- Data Table on France - Year-over-year growth 2024-2029 (%)
- 12.4.4 Italy - Market size and forecast 2024-2029
- Chart on Italy - Market size and forecast 2024-2029 ($ billion)
- Data Table on Italy - Market size and forecast 2024-2029 ($ billion)
- Chart on Italy - Year-over-year growth 2024-2029 (%)
- Data Table on Italy - Year-over-year growth 2024-2029 (%)
- 12.4.5 The Netherlands - Market size and forecast 2024-2029
- Chart on The Netherlands - Market size and forecast 2024-2029 ($ billion)
- Data Table on The Netherlands - Market size and forecast 2024-2029 ($ billion)
- Chart on The Netherlands - Year-over-year growth 2024-2029 (%)
- Data Table on The Netherlands - Year-over-year growth 2024-2029 (%)
- 12.4.6 Spain - Market size and forecast 2024-2029
- Chart on Spain - Market size and forecast 2024-2029 ($ billion)
- Data Table on Spain - Market size and forecast 2024-2029 ($ billion)
- Chart on Spain - Year-over-year growth 2024-2029 (%)
- Data Table on Spain - Year-over-year growth 2024-2029 (%)
- 12.5 Asia - Market size and forecast 2024-2029
- Chart on Asia - Market size and forecast 2024-2029 ($ billion)
- Data Table on Asia - Market size and forecast 2024-2029 ($ billion)
- Chart on Asia - Year-over-year growth 2024-2029 (%)
- Data Table on Asia - Year-over-year growth 2024-2029 (%)
- Chart on Regional Comparison - Asia
- Data Table on Regional Comparison - Asia
- 12.5.1 China - Market size and forecast 2024-2029
- Chart on China - Market size and forecast 2024-2029 ($ billion)
- Data Table on China - Market size and forecast 2024-2029 ($ billion)
- Chart on China - Year-over-year growth 2024-2029 (%)
- Data Table on China - Year-over-year growth 2024-2029 (%)
- 12.5.2 Japan - Market size and forecast 2024-2029
- Chart on Japan - Market size and forecast 2024-2029 ($ billion)
- Data Table on Japan - Market size and forecast 2024-2029 ($ billion)
- Chart on Japan - Year-over-year growth 2024-2029 (%)
- Data Table on Japan - Year-over-year growth 2024-2029 (%)
- 12.5.3 India - Market size and forecast 2024-2029
- Chart on India - Market size and forecast 2024-2029 ($ billion)
- Data Table on India - Market size and forecast 2024-2029 ($ billion)
- Chart on India - Year-over-year growth 2024-2029 (%)
- Data Table on India - Year-over-year growth 2024-2029 (%)
- 12.5.4 South Korea - Market size and forecast 2024-2029
- Chart on South Korea - Market size and forecast 2024-2029 ($ billion)
- Data Table on South Korea - Market size and forecast 2024-2029 ($ billion)
- Chart on South Korea - Year-over-year growth 2024-2029 (%)
- Data Table on South Korea - Year-over-year growth 2024-2029 (%)
- 12.5.5 Indonesia - Market size and forecast 2024-2029
- Chart on Indonesia - Market size and forecast 2024-2029 ($ billion)
- Data Table on Indonesia - Market size and forecast 2024-2029 ($ billion)
- Chart on Indonesia - Year-over-year growth 2024-2029 (%)
- Data Table on Indonesia - Year-over-year growth 2024-2029 (%)
- 12.6 Rest of World (ROW) - Market size and forecast 2024-2029
- Chart on Rest of World (ROW) - Market size and forecast 2024-2029 ($ billion)
- Data Table on Rest of World (ROW) - Market size and forecast 2024-2029 ($ billion)
- Chart on Rest of World (ROW) - Year-over-year growth 2024-2029 (%)
- Data Table on Rest of World (ROW) - Year-over-year growth 2024-2029 (%)
- Chart on Regional Comparison - Rest of World (ROW)
- Data Table on Regional Comparison - Rest of World (ROW)
- 12.6.1 Brazil - Market size and forecast 2024-2029
- Chart on Brazil - Market size and forecast 2024-2029 ($ billion)
- Data Table on Brazil - Market size and forecast 2024-2029 ($ billion)
- Chart on Brazil - Year-over-year growth 2024-2029 (%)
- Data Table on Brazil - Year-over-year growth 2024-2029 (%)
- 12.6.2 Saudi Arabia - Market size and forecast 2024-2029
- Chart on Saudi Arabia - Market size and forecast 2024-2029 ($ billion)
- Data Table on Saudi Arabia - Market size and forecast 2024-2029 ($ billion)
- Chart on Saudi Arabia - Year-over-year growth 2024-2029 (%)
- Data Table on Saudi Arabia - Year-over-year growth 2024-2029 (%)
- 12.6.3 Argentina - Market size and forecast 2024-2029
- Chart on Argentina - Market size and forecast 2024-2029 ($ billion)
- Data Table on Argentina - Market size and forecast 2024-2029 ($ billion)
- Chart on Argentina - Year-over-year growth 2024-2029 (%)
- Data Table on Argentina - Year-over-year growth 2024-2029 (%)
- 12.6.4 Australia - Market size and forecast 2024-2029
- Chart on Australia - Market size and forecast 2024-2029 ($ billion)
- Data Table on Australia - Market size and forecast 2024-2029 ($ billion)
- Chart on Australia - Year-over-year growth 2024-2029 (%)
- Data Table on Australia - Year-over-year growth 2024-2029 (%)
- 12.6.5 UAE - Market size and forecast 2024-2029
- Chart on UAE - Market size and forecast 2024-2029 ($ billion)
- Data Table on UAE - Market size and forecast 2024-2029 ($ billion)
- Chart on UAE - Year-over-year growth 2024-2029 (%)
- Data Table on UAE - Year-over-year growth 2024-2029 (%)
- 12.6.6 Colombia - Market size and forecast 2024-2029
- Chart on Colombia - Market size and forecast 2024-2029 ($ billion)
- Data Table on Colombia - Market size and forecast 2024-2029 ($ billion)
- Chart on Colombia - Year-over-year growth 2024-2029 (%)
- Data Table on Colombia - Year-over-year growth 2024-2029 (%)
- 12.6.7 South Africa - Market size and forecast 2024-2029
- Chart on South Africa - Market size and forecast 2024-2029 ($ billion)
- Data Table on South Africa - Market size and forecast 2024-2029 ($ billion)
- Chart on South Africa - Year-over-year growth 2024-2029 (%)
- Data Table on South Africa - Year-over-year growth 2024-2029 (%)
- 12.6.8 Israel - Market size and forecast 2024-2029
- Chart on Israel - Market size and forecast 2024-2029 ($ billion)
- Data Table on Israel - Market size and forecast 2024-2029 ($ billion)
- Chart on Israel - Year-over-year growth 2024-2029 (%)
- Data Table on Israel - Year-over-year growth 2024-2029 (%)
- 12.6.9 Turkey - Market size and forecast 2024-2029
- Chart on Turkey - Market size and forecast 2024-2029 ($ billion)
- Data Table on Turkey - Market size and forecast 2024-2029 ($ billion)
- Chart on Turkey - Year-over-year growth 2024-2029 (%)
- Data Table on Turkey - Year-over-year growth 2024-2029 (%)
- 12.7 Market opportunity by geography
- Market opportunity by geography ($ billion)
- Data Tables on Market opportunity by geography ($ billion)
13 Drivers, Challenges, and Opportunity
- 13 Drivers, Challenges, and Opportunity
- 13.1 Market drivers
- Growing prevalence of cancer cases
- Many side effects associated with cancer treatment
- Untapped potential in developing countries
- 13.2 Market challenges
- High cost of cancer treatment
- Rising popularity of targeted therapies in developed countries
- Inadequate reimbursement policies
- 13.3 Impact of drivers and challenges
- Impact of drivers and challenges in 2024 and 2029
- 13.4 Market opportunities
- Advent of biosimilars in cancer-associated treatment
- Outsourcing of biosimilars manufacturing activities
- Adoption of various strategies
14 Competitive Landscape
- 14 Competitive Landscape
- 14.1 Overview
- 14.2 Competitive Landscape
- Overview on criticality of inputs and factors of differentiation
- 14.3 Landscape disruption
- Overview on factors of disruption
- 14.4 Industry risks
- Impact of key risks on business
15 Competitive Analysis
- 15 Competitive Analysis
- 15.1 Companies profiled
- 15.2 Company ranking index
- 15.3 Market positioning of companies
- Matrix on companies position and classification
- 15.4 Amgen Inc.
- Amgen Inc. - Overview
- Amgen Inc. - Product / Service
- Amgen Inc. - Key news
- Amgen Inc. - Key offerings
- SWOT
- 15.5 Baxter International Inc.
- Baxter International Inc. - Overview
- Baxter International Inc. - Business segments
- Baxter International Inc. - Key news
- Baxter International Inc. - Key offerings
- Baxter International Inc. - Segment focus
- SWOT
- 15.6 Bayer AG
- Bayer AG - Overview
- Bayer AG - Business segments
- Bayer AG - Key news
- Bayer AG - Key offerings
- Bayer AG - Segment focus
- SWOT
- 15.7 Daiichi Sankyo Co. Ltd.
- Daiichi Sankyo Co. Ltd. - Overview
- Daiichi Sankyo Co. Ltd. - Business segments
- Daiichi Sankyo Co. Ltd. - Key offerings
- Daiichi Sankyo Co. Ltd. - Segment focus
- SWOT
- 15.8 F. Hoffmann La Roche Ltd.
- F. Hoffmann La Roche Ltd. - Overview
- F. Hoffmann La Roche Ltd. - Business segments
- F. Hoffmann La Roche Ltd. - Key news
- F. Hoffmann La Roche Ltd. - Key offerings
- F. Hoffmann La Roche Ltd. - Segment focus
- SWOT
- 15.9 GlaxoSmithKline Plc
- GlaxoSmithKline Plc - Overview
- GlaxoSmithKline Plc - Business segments
- GlaxoSmithKline Plc - Key news
- GlaxoSmithKline Plc - Key offerings
- GlaxoSmithKline Plc - Segment focus
- SWOT
- 15.10 Helsinn Healthcare SA
- Helsinn Healthcare SA - Overview
- Helsinn Healthcare SA - Product / Service
- Helsinn Healthcare SA - Key offerings
- SWOT
- 15.11 Heron Therapeutics Inc.
- Heron Therapeutics Inc. - Overview
- Heron Therapeutics Inc. - Business segments
- Heron Therapeutics Inc. - Key offerings
- Heron Therapeutics Inc. - Segment focus
- SWOT
- 15.12 Johnson and Johnson Services Inc.
- Johnson and Johnson Services Inc. - Overview
- Johnson and Johnson Services Inc. - Business segments
- Johnson and Johnson Services Inc. - Key news
- Johnson and Johnson Services Inc. - Key offerings
- Johnson and Johnson Services Inc. - Segment focus
- SWOT
- 15.13 Kyowa Kirin Co. Ltd.
- Kyowa Kirin Co. Ltd. - Overview
- Kyowa Kirin Co. Ltd. - Business segments
- Kyowa Kirin Co. Ltd. - Key offerings
- Kyowa Kirin Co. Ltd. - Segment focus
- SWOT
- 15.14 Merck and Co. Inc.
- Merck and Co. Inc. - Overview
- Merck and Co. Inc. - Business segments
- Merck and Co. Inc. - Key news
- Merck and Co. Inc. - Key offerings
- Merck and Co. Inc. - Segment focus
- SWOT
- 15.15 Novartis AG
- Novartis AG - Overview
- Novartis AG - Business segments
- Novartis AG - Key news
- Novartis AG - Key offerings
- Novartis AG - Segment focus
- SWOT
- 15.16 Sanofi SA
- Sanofi SA - Overview
- Sanofi SA - Business segments
- Sanofi SA - Key news
- Sanofi SA - Key offerings
- Sanofi SA - Segment focus
- SWOT
- 15.17 Sun Pharmaceutical Industries Ltd.
- Sun Pharmaceutical Industries Ltd. - Overview
- Sun Pharmaceutical Industries Ltd. - Product / Service
- Sun Pharmaceutical Industries Ltd. - Key news
- Sun Pharmaceutical Industries Ltd. - Key offerings
- SWOT
- 15.18 Teva Pharmaceutical Industries Ltd.
- Teva Pharmaceutical Industries Ltd. - Overview
- Teva Pharmaceutical Industries Ltd. - Business segments
- Teva Pharmaceutical Industries Ltd. - Key news
- Teva Pharmaceutical Industries Ltd. - Key offerings
- Teva Pharmaceutical Industries Ltd. - Segment focus
- SWOT
16 Appendix
- 16 Appendix
- 16.1 Scope of the report
- Market definition
- Objectives
- Notes and caveats
- 16.2 Inclusions and exclusions checklist
- Inclusions checklist
- Exclusions checklist
- 16.3 Currency conversion rates for US$
- Currency conversion rates for US$
- 16.4 Research methodology
- 16.5 Data procurement
- 16.6 Data validation
- 16.7 Validation techniques employed for market sizing
- Validation techniques employed for market sizing
- 16.8 Data synthesis
- 16.9 360 degree market analysis
- 360 degree market analysis
- 16.10 List of abbreviations
Research Framework
Technavio presents a detailed picture of the market by way of study, synthesis, and summation of data from multiple sources. The analysts have presented the various facets of the market with a particular focus on identifying the key industry influencers. The data thus presented is comprehensive, reliable, and the result of extensive research, both primary and secondary.
INFORMATION SOURCES
Primary sources
- Manufacturers and suppliers
- Channel partners
- Industry experts
- Strategic decision makers
Secondary sources
- Industry journals and periodicals
- Government data
- Financial reports of key industry players
- Historical data
- Press releases
DATA ANALYSIS
Data Synthesis
- Collation of data
- Estimation of key figures
- Analysis of derived insights
Data Validation
- Triangulation with data models
- Reference against proprietary databases
- Corroboration with industry experts
REPORT WRITING
Qualitative
- Market drivers
- Market challenges
- Market trends
- Five forces analysis
Quantitative
- Market size and forecast
- Market segmentation
- Geographical insights
- Competitive landscape
Get the report (PDF) sent to your email within minutes.
Complimentary full Excel data with your report purchase.
